| Methods |
1‐week washout; 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at end of placebo run‐in; 12‐week double‐blind treatment |
| Participants |
95 postmenopausal women taking HRT regimens that were held constant throughout experimental period;
Moexipril 15 mg: n=47; mean age=56.1(8.0) years; baseline sitting SBP=154.6(11.8) mm Hg, DBP=99.5(3.8) mm Hg, HR=72.7(7.7) bpm;
Placebo: n=48; mean age=57.0(6.8) years; baseline sitting SBP=158.5(13.6) mm Hg, DBP=100.0(3.7) mm Hg, HR=72.4(6.3) bpm |
| Interventions |
Moexipril 15 mg once daily;
Placebo |
| Outcomes |
Adjusted mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported; baseline SD reported; imputed baseline SBP SD for SBP SD of change; imputed overall trial mean SD of change for DBP; change in BP data from text and Figure 1, p. 339; Jadad score=3; funding source= Schwarz Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
